Advertisement

First-Line Nivolumab Plus Oxaliplatin-Based Chemotherapy for HER2-Negative, Unresectable, Advanced or Recurrent Gastric Cancers
Posted: 01/24/2022 | By: Sarah Campen, PharmD

Question 1 of 5

Which of the following statements is TRUE regarding the ATTRACTION-4 trial?

Choose 1

A
The overall survival rate was significantly higher in patients in the nivolumab plus chemotherapy arm compared with the placebo plus chemotherapy arm
B
Decreased neutrophil count was the most common grade 3 or 4 adverse event in both treatment arms
C
The liver was the most common site of metastasis
D
Patients received a median of two previous lines of therapy before enrolling in the trial

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage